Publications by authors named "Mark Lovern"

Claim this Profile
E
Exposure-response analyses of pemigatinib in patients with myeloid/lymphoid neoplasms with fibroblast growth factor receptor 1 rearrangement.
Xiaohua Gong, Ayman Akil, Boris Grinshpun, Jose Francis, Richard Khusial, Mark Lovern

J Chemother· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Training the next generation of pharmacometric modelers: a multisector perspective.
Peter L Bonate, Jeffrey S Barrett, Sihem Ait-Oudhia, Richard Brundage, Brian Corrigan, Mark Lovern

J Pharmacokinet Pharmacodyn· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Training the next generation of pharmacometric modelers: a multisector perspective.
Peter L Bonate, Jeffrey S Barrett, Sihem Ait-Oudhia, Richard Brundage, Brian Corrigan, Mark Lovern

J Pharmacokinet Pharmacodyn· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetic and exposure-response analyses of pemigatinib in patients with advanced solid tumors including cholangiocarcinoma.
Xiaohua Gong, Ayman Akil, Andre Ndi, Tao Ji, Xiang Liu, Mark Lovern

CPT Pharmacometrics Syst Pharmacol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population Pharmacokinetic Modeling for Ceftazidime-Avibactam Renal Dose Adjustments in Pediatric Patients 3 months and Older.
Richard Franzese, Todd Riccobene, Timothy Carrothers, Manoli Vourvahis, Erica Winter, Mark Lovern

Clin Pharmacol Ther· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics of cabotegravir following administration of oral tablet and long-acting intramuscular injection in adult HIV-1-infected and uninfected subjects.
Kelong Han, Mark Baker, Mark Lovern, Prokash Paul, Yuan Xiong

Br J Clin Pharmacol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population Pharmacokinetic Modeling and Probability of Pharmacodynamic Target Attainment for Ceftazidime-Avibactam in Pediatric Patients Aged 3 Months and Older.
Richard C Franzese, Lynn McFadyen, Kenny J Watson, Todd Riccobene, Timothy J Carrothers, Mark Lovern

Clin Pharmacol Ther· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and pharmacodynamics of Abelacimab (MAA868), a novel dual inhibitor of Factor XI and Factor XIa.
B Alexander Yi, Debra Freedholm, Nancy Widener, Xiaohui Wang, Emilie Simard, Mark Lovern

J Thromb Haemost· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Probenecid inhibits SARS-CoV-2 replication in vivo and in vitro.
Jackelyn Murray, Robert J Hogan, David E Martin, Kathy Blahunka, Fred D Sancilio, Mark Lovern

Sci Rep· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Considerations in the Selection of Renal Dosage Adjustments for Patients with Serious Infections and Lessons Learned from the Development of Ceftazidime-Avibactam.
Jianguo Li, Mark Lovern, Todd Riccobene, Timothy J Carrothers, Paul Newell

Antimicrob Agents Chemother· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Ceftazidime-Avibactam Population Pharmacokinetic Modeling and Pharmacodynamic Target Attainment Across Adult Indications and Patient Subgroups.
Jianguo Li, Mark Lovern, Michelle L Green, Joannellyn Chiu, Diansong Zhou

Clin Transl Sci· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, double blind, dose escalation, first time in human study to assess the safety, tolerability, pharmacokinetics, and antiviral activity of single doses of GSK2485852 in chronically infected hepatitis C subjects.
David A Wilfret, Jill Walker, Christian Voitenleitner, Sharon Baptiste-Brown, Mark Lovern

Clin Pharmacol Drug Dev· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
Zanamivir pharmacokinetics and pulmonary penetration into epithelial lining fluid following intravenous or oral inhaled administration to healthy adult subjects.
Mark J Shelton, Mark Lovern, Judith Ng-Cashin, Lori Jones, Elizabeth Gould

Antimicrob Agents Chemother· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetic and pharmacodynamic analysis in allergic diseases.
Mark Lovern, Maria-Laura Sargentini-Maier, Christian Otoul, Jean-Baptiste Watelet

Drug Metab Rev· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic study of different dosing regimens of levonorgestrel for emergency contraception in healthy women.
Elof Johansson, Vivian Brache, Frank Alvarez, Anibal Faundes, Leila Cochon, Mark Lovern

Hum Reprod· June 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis